Intrinsiqq
Globus Medical Inc. logo

Globus Medical Inc. Quality Score

GMED

⊜ Compare
Quality71

Growth remains strong (avg 100/100), but business quality is pulling the composite down (avg 45/100).

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
80/100
22.4x

20–25x range, moderate premium

Cash Flow Multiple
90/100
15.5x

Under 20x cash flow, well covered

Revenue Growth
100/100
32.4%

Above 10% CAGR, strong compounder

Cash Flow Growth
100/100
64.0%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution
0/100
33.8%

Heavy dilution above 5%

Margin Trend
20/100
-2.0pp

Modest contraction, within normal range

Capital Structure
100/100
-$483M

Net cash position, no leverage concern

2022
$446M
$6.00M
2023
$518M
$521M
2024
$890M
$538M
2025
$557M
$119M
TTM
$595M
$112M
CashDebt
Return on Capital
60/100
10.9%

10–15%, respectable returns

Customize WeightsPremiumUpgrade

Globus Medical (GMED) quality: score, margins and returns

Globus Medical (GMED) scores 71/100 on Intrinsiqq's quality score (a solid business), a weighted blend of 8 metrics each scored 0 to 100, on 20.3% operating margins and 10.9% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Globus Medical (GMED) a high-quality business?+

Globus Medical scores 71 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a solid business on these measures. Recent figures include a 20.3% operating margin and a 10.9% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Globus Medical's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from GMED's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Globus Medical scores well and where it falls behind.

What is Globus Medical's return on invested capital (ROIC)?+

Globus Medical earns about 10.9% on its invested capital, which is solid. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to GMED's margins and growth on this scorecard to judge durability.

How profitable is Globus Medical?+

Globus Medical runs an operating margin of about 20.3% and a net margin of about 17.0%. Revenue has grown at roughly 30.1% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 4 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 18 Sept 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Surgical & Medical Instruments & Apparatus · Pick stocks to compare with GMED

CompareIntrinsic value
MMEDMiniMed Group, Inc.
$19.29+2.33%25
PODDInsulet Corporation
$165.02+6.56%75
WSTWest Pharmaceutical Services, Inc.
$408.78+0.44%46
ICUIIcu Medical Inc.
$172.62+6.67%46
TFXTeleflex Incorporated
$149.87+7.09%16
IARTIntegra LifeSciences Holdings Corporation
$14.82+8.73%28
MMSIMerit Medical Systems, Inc.
$90.63+7.69%61
PENPenumbra Inc.
$322.45+0.76%72

Held by ETFs

GMED is in 139 US ETFs. The largest of them, with GMED's weight in each:

Spot a number that looks wrong? Check it in GMED's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing GMED

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.